期刊文献+

酪氨酸激酶获得性突变JAK2 Val617Phe与骨髓增殖性疾病 被引量:1

原文传递
导出
摘要 骨髓增殖性疾病(MPD)是克隆性造血干细胞疾病,以骨髓中一系或多系细胞增殖、外周血出现过多的成熟或幼稚细胞为特征。MPD主要包括下列一组疾病:真性红细胞增多症(PV)、原发性血小板增多症(ET)、原发性骨髓纤维化(IMF)、慢性粒细胞白血病(CML)以及少见亚型如嗜酸粒细胞增多症(HES)、慢性嗜酸粒细胞白血病(CEL)等。已明确9号和22号染色体易位所产生的融合基因bcr—abl是CML发病的关键环节;近年来的研究表明,HES中也存在特征性分子遗传学改变——FIPlL1-PDGFRA融合基因。但PV、ET、IMF等其他bcr—abl阴性的MPD基础研究进展相对缓慢。2005年的几项研究表明,在大多数PV以及部分ET和IMF中存在高致病性的获得性突变——酪氨酸激酶JAK2V舶17Phe。该突变的发现令人瞩目,为揭示MPD的发病机制提供了新的思路。
出处 《中华血液学杂志》 CAS CSCD 北大核心 2006年第7期497-499,共3页 Chinese Journal of Hematology
  • 相关文献

参考文献22

  • 1Vardiman JW,Harris NL,Brunning RD.The Word Health Orgnization (WHO) classification of the myeloid neoplasms.Blood,2002,100:2292 -2302.
  • 2Cools J,DeAngelo DJ,Gotlib J,et al.A tyrosine kinase created by fusion of the PDGFRA and FIP1 L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.N Engl J Med,2003,348:1201-1214.
  • 3张广森,李斌,裴敏飞,戴崇文,郑文莉,申建凯.高嗜酸性粒细胞综合征FIP1L1-PDGFRA融合基因和转录活化因子5蛋白检测[J].中华医学杂志,2004,84(18):1541-1544. 被引量:5
  • 4Goldman JM,Melo JV.Chronic myeloid leukemia-advances in biology and new approaches to treatment.N Engl J Med,2003,349:1451-1464.
  • 5Prchal JF,Axelrad AA.Bone-marrow responses in polycythemia vera.N Engl J Med,1974,290:1382-1384.
  • 6Zanjani ED,Lutton JD,Hoffman R,et al.Erythroid colony formation by polycythemia vera bone marrow in vitro.Dependence on erythropoietin.Clin Invest,1977,59:841-848.
  • 7Dai CH,Krantz SB,Green WF,et al.Polycythaemia vera.Ⅲ.Burst-forming units-erythroid (BFU-E) response to stem cell factor and c-kit roceptor expression.Br J Haematol,1994,86:12-21.
  • 8Mirza AM,Ezzat S,Axelrad AA.Insulin-like growth factor binding protein-1 is elevated in patients with polycythemia vera and stimulates erythroid burst formation in vitro.Blood,1997,89:1862-1869.
  • 9Ihle JN.Cytokine receptor signaling.Nature,1995,377:591-594.
  • 10Roder S,Steimle C,Meinhardt G,et al.STAT3 is constitutively active in some patients with Polycythemia rubra vera.Exp Hematol,2001,29:694-702.

二级参考文献8

  • 1Chusid MJ, Dale DC, West BC, et al. The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature. Medicine, 1975, 54:1-27.
  • 2Schaller JL, Burkland GA. Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate. Med Gen Med, 2001, 3:9.
  • 3Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med, 2003, 348:1201-1214.
  • 4Griffins JH, Leung J, Bruner RJ, et al. Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome. Proc Natl Acad Sci USA, 2003, 100:7830-7835.
  • 5Gotlib J, Cools J, James M, et al. The FIP1L1-PDGFRA fusion tyrosine kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia: implications for diagnosis, classification, and management. Blood, 2004,103:2879-2891.
  • 6Cools J,Stover EH,Wlodarska I,et al. The FIP1L1-PDGFRA kinase in hypereosinophilic syndrome and chronic eosinophilic leukemia. Curr opin Heamotol, 2004,11:51-57.
  • 7Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood, 2
  • 8Xi S, Zhang Q, Gooding WE, et al. Constitutive activation of Stat5b contributes to carcinogenesis in vivo. Cancer Res, 2003, 63:6763-6771.

共引文献4

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部